The UK BIA Antibody Taskforce is set to take combinations into further development as a cocktail
News
Novartis sets sights on potential COVID-19 antivirals from Molecular Partners
Collaboration includes two therapeutic candidates – MP0420 and MP0423
BMS collaborates with insitro to develop drugs for ALS
Agreement will also see companies develop treatments for frontotemporal dementia
NICE recommends testing womb cancer patients for inherited condition
New guidance based on research from University of Manchester
Sanofi teams up with MSD to test new oncology treatment
French pharma will test investigational candidate alongside MSD’s Keytruda
Oxford start-up Base Genomics acquired by Exact Sciences
Acquisition will enable Base Genomics to accelerate clinical and commercial development
UK’s MHRA starts rolling review of Moderna’s COVID-19 vaccine
Process can help to reduce the time to authorisation of the vaccine
Enhertu bags US priority review for HER2+ gastric cancer
FDA action date for regulatory decision set during first quarter of 2021
Sanofi and GSK to provide COVID-19 vaccine doses to COVAX Facility
Agreement will see vaccine developers make available 200 million doses
Sensyne Health signs new NHS research agreement
Strategic research agreement announced with Milton Keynes University Hospital Foundation Trust
Novartis’ rare renal disease candidate shows promise in phase II
Investigational oral treatment is being investigated in C3 glomerulopathy
Bayer’s Nubeqa wins NICE prostate cancer backing
Drug authorised for use in non-metastatic castration-resistant prostate cancer
AstraZeneca resumes US phase III COVID-19 vaccine trial
Trial was paused in September following participant illness
Bayer to acquire cell and gene therapy specialist AskBio
Deal could be worth up to $4bn dependent on success milestones
Parkinson’s UK partners with UCL on phase II trial
Trial will investigate chemotherapy drug to alleviate hallucinations in people with Parkinson’s
